Alectinib is a first-line treatment for patients withadvanced non-small cell lung cancer(NSCLC)harbor-ing anaplastic lymphoma kinase-positive(ALK+)driveraberrations with a median progression-free survival of 35months ...Alectinib is a first-line treatment for patients withadvanced non-small cell lung cancer(NSCLC)harbor-ing anaplastic lymphoma kinase-positive(ALK+)driveraberrations with a median progression-free survival of 35months and a 5-year overall survival of 63%[1].Currently,alectinib also shows improvement as an adjuvant treat-ment in resected stage IA-IIIB ALK+NSCLC[2].Alectinibhas a mild safety profile,but a notable underreported side-effect is weight gain[3].Studies show sarcopenic obesityrates doubling from 24%to 47%in the first year of treatment[3],with persisting weight gain appearing early[4].Givenpatients’extended survival,this poses risks for metabolic,cardiovascular,and psychological health.展开更多
文摘Alectinib is a first-line treatment for patients withadvanced non-small cell lung cancer(NSCLC)harbor-ing anaplastic lymphoma kinase-positive(ALK+)driveraberrations with a median progression-free survival of 35months and a 5-year overall survival of 63%[1].Currently,alectinib also shows improvement as an adjuvant treat-ment in resected stage IA-IIIB ALK+NSCLC[2].Alectinibhas a mild safety profile,but a notable underreported side-effect is weight gain[3].Studies show sarcopenic obesityrates doubling from 24%to 47%in the first year of treatment[3],with persisting weight gain appearing early[4].Givenpatients’extended survival,this poses risks for metabolic,cardiovascular,and psychological health.
